Sopharma AD-Sofia (WAR:SPH) Other Current Receivables: zł96 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SPH Sopharma AD-Sofia WAR:SPH
67 GF Score
Price zł7.28
GF Value zł13.42
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Other Current Receivables?

Sopharma AD-Sofia WAR:SPH +0.55% 67 Other Current Receivables is zł96 Mil as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.42 (Possible Value Trap). The stock has 4 warning signs investors should review.

Sopharma AD-Sofia's Other Current Receivables for the quarter that ended in Mar. 2026 was zł96 Mil.

Sopharma AD-Sofia's quarterly Other Current Receivables declined from Sep. 2025 (zł83.80 Mil) to Dec. 2025 (zł67.05 Mil) but then increased from Dec. 2025 (zł67.05 Mil) to Mar. 2026 (zł96.22 Mil).

Sopharma AD-Sofia's annual Other Current Receivables declined from Dec. 2023 (zł85.45 Mil) to Dec. 2024 (zł68.13 Mil) and declined from Dec. 2024 (zł68.13 Mil) to Dec. 2025 (zł67.05 Mil).

Sopharma AD-Sofia Other Current Receivables Related Terms

Sopharma AD-Sofia Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Other Current Receivables Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.13 79.73 85.45 68.13 67.05

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.72 76.13 83.80 67.05 96.22
WAR:SPH
67GF Score
Sopharma AD-Sofia WAR:SPH
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of zł96 Mil mean?
Sopharma AD-Sofia (WAR:SPH) has a Other Current Receivables of zł96 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Other Current Receivables too high?
Sopharma AD-Sofia's current Other Current Receivables is zł96 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Other Current Receivables compare to MCK and CAH?
Sopharma AD-Sofia's Other Current Receivables of zł96 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Distribution company?
A good Other Current Receivables depends on the Medical Distribution industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Other Current Receivables is zł96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.42, compared to a current price of zł7.28 — trading 45.8% below its estimated fair value. The current Other Current Receivables is zł96 Mil. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Other Current Receivables is zł96 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.28 is trading 45.8% below its estimated GF Value™ of zł13.42. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • Other Current Receivables: zł96 Mil
  • GF Value™: zł13.42 vs. price of zł7.28 (45.8% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score

Get the complete analysis for WAR:SPH

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.28
Price
zł13.42
GF Value